History of Changes for Study: NCT03626311
Omega-3 Replacement With Krill Oil in Disease Management of SLE (ORKIDS)
Latest version (submitted October 11, 2021) on
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 August 8, 2018 None (earliest Version on record)
2 December 14, 2018 Recruitment Status, Study Status and Contacts/Locations
3 July 6, 2019 Study Status and Contacts/Locations
4 July 7, 2020 Study Status
5 January 14, 2021 Recruitment Status, Study Status, Contacts/Locations and Study Design
6 October 11, 2021 Recruitment Status and Study Status
Comparison Format:

Scroll up to access the controls

Study NCT03626311
Submitted Date:  August 8, 2018 (v1)

Open or close this module Study Identification
Unique Protocol ID: AMP-004
Brief Title: Omega-3 Replacement With Krill Oil in Disease Management of SLE (ORKIDS)
Official Title: A Double-Blind, Placebo-Controlled Randomized, Multicenter Study to Assess Changes in Omega-3 Index in Erythrocytes and Health Benefit After 24 Weeks of Daily Consumption of AKBM-3031 (Omega-3 Phospholipids From Krill), Followed by a 24 Week Open-Label Extension, in Patients With Systemic Lupus Erythematosus (SLE)
Secondary IDs:
Open or close this module Study Status
Record Verification: August 2018
Overall Status: Not yet recruiting
Study Start: August 2018
Primary Completion: April 2020 [Anticipated]
Study Completion: December 2020 [Anticipated]
First Submitted: June 6, 2018
First Submitted that
Met QC Criteria:
August 8, 2018
First Posted: August 13, 2018 [Actual]
Last Update Submitted that
Met QC Criteria:
August 8, 2018
Last Update Posted: August 13, 2018 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Aker Biomarine Antarctic AS
Responsible Party: Sponsor
Collaborators: Ampel BioSolutions, LLC
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: A randomized, double-blind controlled, multicenter study in SLE patients given AKBM-3031or placebo for 24 weeks (randomized period) and followed by an open label extension (OLE) treatment with AKBM-3031 for the next 24 weeks. Patients will be maintained on stable doses of background medications, except for glucocorticoids. Decreases in doses of glucocorticoids will be encouraged during the first 20 weeks of both the randomized and open label extension portions of the trial. Stable doses of glucocorticoids and other background medications are required during weeks 20-22 and 44-48.If indicated by the PI, brief increases in corticosteroids are permitted during the first 20 weeks of both the blinded and open label extension portion of the trial. The increase in prednisone (or equivalent) dose is limited to 2X the back-ground level to a maximum of20 mg/day for a maximum of 1 week (7 days) or to a single administration of intravenous methylprednisolone or equivalent at a maximum dose of 500mg. Stable doses of glucocorticoids and other background medications are required during weeks 20-22 and 44-48
Detailed Description:
Open or close this module Conditions
Conditions: Systemic Lupus Erythematosus (SLE)
Keywords: Lupus
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Supportive Care
Study Phase: Not Applicable
Interventional Study Model: Parallel Assignment
Eligible patients will be randomized (1:1) to receive either AKBM-3031 or placebo during the randomized period.The randomized subjects will take (4)1 gram capsules of product or placebo every day, (2) 1 gram capsules in the morning and (2) 1 gram capsules in the evening, for a total of 4 grams per day for the first 24 weeks (randomized period). All subjects may continue to a 24-week extension (Open Label Extension) of open-label AKBM-3031, 4 grams/day. The total study duration per subject is 48 weeks. With about 4 months for site activation and 12 months for enrollment, the entire study is expected to complete in approximately 116 weeks.
Number of Arms: 2
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation: Randomized
Enrollment: 76 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: AKBM-3031
4g/day (2 capsules BID)
Dietary Supplement: AKBM-3031

Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.

The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use.

Other Names:
  • Krill Oil
Placebo Comparator: Placebo
4g/day (2 capsules BID)
The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Difference in the ratio of omega-3 to omega-6 measured through lab tests on red blood cells from baseline through the end of the study in patients with generalized lupus.
[ Time Frame: Baseline to 24 weeks ]

Secondary Outcome Measures:
1. Effect of correction of omega-3 deficiency measured by SLE biomarkers of immune function.
[ Time Frame: Baseline to 24 weeks ]

2. Effect of correction of omega-3 deficiency measured by both clinician and patient reported outcomes collected at clinic visits.
[ Time Frame: Baseline to 24 weeks ]

3. Change in health related quality of life measured using the Medical Outcomes study Short Form 36 (SF-36).
[ Time Frame: Baseline to 24 weeks ]

Both physical component scores (PCS) and mental component scores (MCS) will be assessed. Change in both PCS and MCS will be evaluated over the time of this study. The SF-36 is a patient recorded survey of health related quality of life, consisting of the evaluation of 8 domains, and then scored from 0-100. The higher score correlates to better health-related quality of life. The mean for healthy individuals is 50.
4. Difference of number of patients with reported adverse events or changes in lab parameters while taking AKBM-3031.
[ Time Frame: Baseline to 24 weeks ]

Examples of patient reported adverse events include gastrointestinal symptoms, infection, unexplained bleeding, etc. Examples of lab parameters indicating an adverse event are changes in liver function tests, urinalysis, and hematologic parameters (which could be considered an adverse event).
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No

Inclusion Criteria:

  1. Male or female aged at least 18 years old.
  2. Capable of giving written consent on an Institutional Review Board or IRB-approved Informed Consent Form prior to any study-specific evaluation
  3. Have a clinical diagnosis of SLE with at least 4 of the 11 American College of Rheumatology (ACR) criteria as modified in 1997 or meeting SLICC criteria
  4. SLE activity (SLEDAI ≥6)
  5. On a stable SLE treatment regimen consisting of a stable dosage of any of the following medications for a period of at least 30 days prior to Baseline (i.e., day of 1st dose of study agent):
    1. Corticosteroids. Corticosteroids (< 20 mg prednisone or equivalent per day)
    2. Hydroxychloroquine or equivalent anti-malarial
    3. Other immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium at no more than 2 grams/day), calcineurin inhibitors (e.g., tacrolimus,cyclosporine)
    4. Belimumab dose must be stable for 60 days prior to Baseline
    5. Cyclophosphamide dose must be stable for the last 90 days prior to Baseline
    6. Have not received rituximab within 6 months
  6. Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less; see Addendum 1 for a list of fish and seafood considered to be fatty.

Exclusion Criteria:

Patients are excluded from the study if any of the following criteria are met:

  1. Have rapidly progressive neurologic or renal disease
  2. Currently taking an omega-3 prescription drug (e.g. Lovaza®, Vascepa®, etc.) or as medical food (e.g. Vascazen®, Vayarin, Onemia™etc.)
  3. Present or recent use (within 3 months of screening) of any OTC fish or krill oil dietary supplement., or any long-chain omega-3 fatty acid dietary supplement (e.g.,MegaRed)
  4. Have severe lupus kidney disease (defined by proteinuria > 6 gm/24 hour or equivalent using spot urine protein to creatinine ratio, or serum creatinine > 2.5mg/dL)
  5. Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not related to SLE (i.e., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious) which, in the opinion of the treating physician, could confound the results of the study or put the patients at undue risk
  6. Have received intravenous glucocorticoids at a dosage of ≥ 500 mg daily within the past month
  7. Require anti-coagulation with coumadin, clopidogrel, dalteparin, dypyridamole, enoxaparin, heparin or ticlopidine. Low dose aspirin (<325 mg/day) is permitted.
  8. Receiving orlistat (Xenical, Alli) and have refused to discontinue at baseline and throughout the trial.
  9. History of allergy to seafood or shellfish
  10. Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Baseline
  11. Are pregnant or lactating
  12. Recent participation in a clinical trial with an experimental agent in the past 6 weeks, or 5 half-lives of the study drug, whichever is longer
  13. Have a Grade 3 or greater laboratory abnormality based on the Adverse Event Severity Grading Tables (CTCAE), except for the following that are allowed:
    1. Stable Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy
    2. Stable Grade 3 hypoalbuminemia due to chronic lupus nephritis, and not related to liver disease
    3. Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes, or viral hepatitis. If present, any abnormalities in the ALT or Alanine Transaminase and/or AST or Aspartate Transaminase must be < Grade 2.
    4. Stable Grade 3 neutropenia or stable Grade 3 white blood cell count due to lupus.
  14. Patients will be excluded from the study based on the following bone marrow, hepatic and renal function values:
    1. Hemoglobin: < 8.0 gm/dL
    2. Platelets: <50,000/mm
    3. ANC < 1.0 x 103/mm
    4. AST or ALT >2.5 x Upper Limit of Normal unless related to primary disease.
    5. Creatinine clearance ≤ 25ml/min per 1.73m2
Open or close this module Contacts/Locations
Central Contact Person: Audrey Ogendi, MPH
Telephone: 434-977-2675
Central Contact Backup: Debbie Scott
Telephone: 434-977-2675
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services